API | bexsero

bexsero Report issue

Vaccine Experimental

Active Ingredient History

NOW

Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (13)

Research & Development (13)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)

Healthy Volunteers (Phase 3)

HIV (Phase 4)

HIV Infections (Phase 4)

Meningitis, Meningococcal (Phase 4)

Meningococcal Infections (Phase 3)

Meningococcal Vaccines (Phase 2)

Respiratory Syncytial Virus Infections (Phase 1)

Risk-Taking (Phase 3)

Splenectomy (Phase 3)

Unsafe Sex (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial Organizations: 13

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue